Eli Lilly: $2.75 Billion Deal Secures Next Generation AI Compounds!

Eli Lilly expands its portfolio in AI-driven drug discovery through an agreement worth up to $2.75 billion with biotech company Insilico Medicine. The US pharmaceutical company acquires the worldwide marketing rights for drugs that have been developed entirely through artificial intelligence. The contract structure includes an initial upfront payment of $115 million to the publicly listed company based in Hong Kong. The remaining payments will be made upon reaching specific regulatory and commercial milestones. The existing software collaboration...